-
Je něco špatně v tomto záznamu ?
In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
L. Malisova, I. Vrbova, K. Pomorska, V. Jakubu, H. Zemlickova
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
PubMed
37610876
DOI
10.1089/mdr.2023.0090
Knihovny.cz E-zdroje
- MeSH
- antibakteriální látky * farmakologie MeSH
- beta-laktamasy genetika metabolismus MeSH
- cefiderokol MeSH
- Enterobacteriaceae genetika metabolismus MeSH
- karbapenemy * farmakologie MeSH
- mikrobiální testy citlivosti MeSH
- Pseudomonas aeruginosa MeSH
- Publikační typ
- časopisecké články MeSH
The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order Enterobacterales, and 40 strains of Pseudomonas aeruginosa. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, blaIMP, blaGES) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (n = 149) strains of the order Enterobacterales and 77.5% (n = 31) of P. aeruginosa isolates were inhibited at minimal inhibitory concentration (MIC) ≤2 mg/L. Values MIC50/MIC90 were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for P. aeruginosa. One isolate (Klebsiella pneumoniae) harboring two carbapenemases (blaOXA-48, blaNDM) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, blaNDM carbapenemase prevailed (43.3%, n = 29), followed by blaOXA-48 (31.3%, n = 21) and blaKPC (4.5%, n = 3). blaIMP (n = 8) and blaVIM (n = 1) metallo-β-lactamases dominated in cefiderocol-resistant P. aeruginosa (n = 9) isolates. Very good susceptibility (100%) to this drug showed blaGES-positive strains of P. aeruginosa (n = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (n = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001154
- 003
- CZ-PrNML
- 005
- 20241231101948.0
- 007
- ta
- 008
- 240109s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1089/mdr.2023.0090 $2 doi
- 035 __
- $a (PubMed)37610876
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Malisova, Lucia $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $u Department of Microbiology, 3rd Faculty of Medicine, Kralovske Vinohrady University Hospital and National Institute of Public Health, Charles University, Prague, Czech Republic
- 245 10
- $a In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa / $c L. Malisova, I. Vrbova, K. Pomorska, V. Jakubu, H. Zemlickova
- 520 9_
- $a The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order Enterobacterales, and 40 strains of Pseudomonas aeruginosa. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, blaIMP, blaGES) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (n = 149) strains of the order Enterobacterales and 77.5% (n = 31) of P. aeruginosa isolates were inhibited at minimal inhibitory concentration (MIC) ≤2 mg/L. Values MIC50/MIC90 were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for P. aeruginosa. One isolate (Klebsiella pneumoniae) harboring two carbapenemases (blaOXA-48, blaNDM) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, blaNDM carbapenemase prevailed (43.3%, n = 29), followed by blaOXA-48 (31.3%, n = 21) and blaKPC (4.5%, n = 3). blaIMP (n = 8) and blaVIM (n = 1) metallo-β-lactamases dominated in cefiderocol-resistant P. aeruginosa (n = 9) isolates. Very good susceptibility (100%) to this drug showed blaGES-positive strains of P. aeruginosa (n = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (n = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.
- 650 12
- $a karbapenemy $x farmakologie $7 D015780
- 650 12
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 _2
- $a Pseudomonas aeruginosa $7 D011550
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a beta-laktamasy $x genetika $x metabolismus $7 D001618
- 650 _2
- $a Enterobacteriaceae $x genetika $x metabolismus $7 D004755
- 650 _7
- $a cefiderokol $7 D000097602 $2 czmesh
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vrbová, Iveta $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $7 xx0327427
- 700 1_
- $a Pomorska, Katarina $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic
- 700 1_
- $a Jakubu, Vladislav $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $u Department of Microbiology, 3rd Faculty of Medicine, Kralovske Vinohrady University Hospital and National Institute of Public Health, Charles University, Prague, Czech Republic
- 700 1_
- $a Zemlickova, Helena $u National Reference Laboratory for Antibiotics, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $u Department of Microbiology, 3rd Faculty of Medicine, Kralovske Vinohrady University Hospital and National Institute of Public Health, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00008749 $t Microbial drug resistance $x 1931-8448 $g Roč. 29, č. 10 (2023), s. 485-491
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37610876 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20241231101947 $b ABA008
- 999 __
- $a ok $b bmc $g 2049637 $s 1210848
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 29 $c 10 $d 485-491 $e 20230822 $i 1931-8448 $m Microbial drug resistance $n Microb Drug Resist $x MED00008749
- LZP __
- $a Pubmed-20240109